EA022283B1 - Лекарственный препарат, содержащий бензилдиметил[3-(миристоиламино)пропил]аммония хлорид - Google Patents
Лекарственный препарат, содержащий бензилдиметил[3-(миристоиламино)пропил]аммония хлорид Download PDFInfo
- Publication number
- EA022283B1 EA022283B1 EA201201158A EA201201158A EA022283B1 EA 022283 B1 EA022283 B1 EA 022283B1 EA 201201158 A EA201201158 A EA 201201158A EA 201201158 A EA201201158 A EA 201201158A EA 022283 B1 EA022283 B1 EA 022283B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- propyl
- myristoylamino
- drug according
- dimethyl
- amine
- Prior art date
Links
- JQQZCIIDNVIQKO-UHFFFAOYSA-N benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC1=CC=CC=C1 JQQZCIIDNVIQKO-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 150000004682 monohydrates Chemical group 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 40
- 241001465754 Metazoa Species 0.000 claims description 25
- -1 dimethyl [3- (myristoylamino) propyl] amine Chemical class 0.000 claims description 24
- 239000002674 ointment Substances 0.000 claims description 14
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 230000002421 anti-septic effect Effects 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 4
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims description 4
- 235000019270 ammonium chloride Nutrition 0.000 claims description 4
- 229940064004 antiseptic throat preparations Drugs 0.000 claims description 4
- 239000000850 decongestant Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- 229960003150 bupivacaine Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 2
- 229940124581 decongestants Drugs 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229960002475 halometasone Drugs 0.000 claims description 2
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- 229960005016 naphazoline Drugs 0.000 claims description 2
- 229960001528 oxymetazoline Drugs 0.000 claims description 2
- 229960001802 phenylephrine Drugs 0.000 claims description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 2
- 229960000395 phenylpropanolamine Drugs 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229960003908 pseudoephedrine Drugs 0.000 claims description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 2
- 229960000888 rimantadine Drugs 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims description 2
- 229950002569 trimecaine Drugs 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 229960000833 xylometazoline Drugs 0.000 claims description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960001347 fluocinolone acetonide Drugs 0.000 claims 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- IFYDWYVPVAMGRO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)NCCCN(C)C IFYDWYVPVAMGRO-UHFFFAOYSA-N 0.000 abstract description 8
- 239000008063 pharmaceutical solvent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 26
- 210000001508 eye Anatomy 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000000622 irritating effect Effects 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 4
- 229940073608 benzyl chloride Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010037569 Purulent discharge Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001150 spermicidal effect Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 241000700112 Chinchilla Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- YEAYHNRJRKXWNV-UHFFFAOYSA-O benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium Chemical compound CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC1=CC=CC=C1 YEAYHNRJRKXWNV-UHFFFAOYSA-O 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 231100000086 high toxicity Toxicity 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 239000008311 hydrophilic ointment Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- VEPZOLKTNZOTTQ-UHFFFAOYSA-N 1-butyl-n-(2,4,6-trimethylphenyl)pyrrolidine-2-carboxamide Chemical compound CCCCN1CCCC1C(=O)NC1=C(C)C=C(C)C=C1C VEPZOLKTNZOTTQ-UHFFFAOYSA-N 0.000 description 1
- ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical compound NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000001894 hemadsorption Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000005582 sexual transmission Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/001056 WO2011100994A1 (de) | 2010-02-19 | 2010-02-19 | Arzneimittel enthaltend myramistin |
| PCT/EP2011/000691 WO2011101113A1 (de) | 2010-02-19 | 2011-02-15 | Arzneimittel enthaltend myramistin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201201158A1 EA201201158A1 (ru) | 2013-02-28 |
| EA022283B1 true EA022283B1 (ru) | 2015-12-30 |
Family
ID=42668884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201201158A EA022283B1 (ru) | 2010-02-19 | 2011-02-15 | Лекарственный препарат, содержащий бензилдиметил[3-(миристоиламино)пропил]аммония хлорид |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2536400B1 (enExample) |
| JP (1) | JP5746224B2 (enExample) |
| KR (1) | KR101744895B1 (enExample) |
| CN (1) | CN102869354B (enExample) |
| AU (1) | AU2011217530B2 (enExample) |
| BR (1) | BR112012020828B1 (enExample) |
| CY (1) | CY1115833T1 (enExample) |
| DK (1) | DK2536400T3 (enExample) |
| EA (1) | EA022283B1 (enExample) |
| ES (1) | ES2524379T3 (enExample) |
| GE (1) | GEP20135942B (enExample) |
| HR (1) | HRP20141173T1 (enExample) |
| IL (1) | IL221501A (enExample) |
| MD (1) | MD4411C1 (enExample) |
| MX (1) | MX2012009646A (enExample) |
| PL (1) | PL2536400T3 (enExample) |
| PT (1) | PT2536400E (enExample) |
| SI (1) | SI2536400T1 (enExample) |
| UA (1) | UA103968C2 (enExample) |
| WO (2) | WO2011100994A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014175757A1 (ru) * | 2013-04-22 | 2014-10-30 | Общество с ограниченной ответственностью "Нанобиотех" | Антисептический ветеринарный препарат и способы его использования |
| RU2542376C1 (ru) * | 2013-07-30 | 2015-02-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Средство для лечения гнойно-воспалительных процессов мягких тканей и слизистых оболочек |
| CN109456218A (zh) * | 2018-12-17 | 2019-03-12 | 山东诚汇双达药业有限公司 | 一种盐酸三甲卡因的生产方法 |
| GB202003240D0 (en) * | 2020-03-05 | 2020-04-22 | Ecosynth Nv | Antiviral treatment |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2459062A (en) * | 1944-02-08 | 1949-01-11 | American Cyanamid Co | Quaternary ammonium compounds |
| US4093711A (en) * | 1976-08-13 | 1978-06-06 | Noxell Corporation | Oral hygiene |
| WO1993000892A1 (fr) * | 1991-07-10 | 1993-01-21 | Jury Semenovich Krivoshein | Preparation pharmaceutique |
| SU1796185A1 (ru) * | 1990-06-23 | 1993-02-23 | Adolina P Rudko | Фунгицид 2 |
| RU2157214C2 (ru) * | 1998-04-16 | 2000-10-10 | Государственный научный центр лекарственных средств | Противовоспалительное и антимикробное лекарственное средство для местного применения |
| RU2161961C1 (ru) * | 2000-03-17 | 2001-01-20 | Кривошеин Юрий Семенович | Лекарственный препарат |
| UA64800C2 (uk) * | 2000-04-27 | 2004-03-15 | Юрій Семенович Кривошеін | Очний антисептик |
| US20040058924A1 (en) * | 2000-12-20 | 2004-03-25 | Schlitzer Ronald L. | Use of amidoamines to treat or prevent acanthamoeba and fungal infections |
| UA67795C2 (uk) * | 2000-06-26 | 2004-07-15 | Yurii Semenovych Kryvoshein | Склад для лікування опікових ран, який включає мірамістин |
| EP1634590A1 (de) * | 2003-06-04 | 2006-03-15 | Megainpharm GmbH | Coronavirus-inaktivierendes mittel |
| WO2007136558A2 (en) * | 2006-05-10 | 2007-11-29 | S.K. Pharmaceutical, Inc. | Synergistically enhanced disinfecting solutions |
| DE102008039254A1 (de) * | 2008-08-20 | 2010-02-25 | Megainpharm Gmbh | Arzneimittel |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5393491A (en) | 1993-09-22 | 1995-02-28 | Alcon Laboratories, Inc. | Use of amidoamines in ophthalmic compositions |
| UA30143C2 (uk) * | 1997-12-30 | 2001-11-15 | Юрій Семенович Кривошеін | Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань |
| RU2177314C2 (ru) | 2000-03-22 | 2001-12-27 | Кривошеин Юрий Семенович | Состав с антисептическими, репаративными и болеутоляющими свойствами |
| RU2173142C1 (ru) | 2000-04-18 | 2001-09-10 | Кривошеин Юрий Семенович | Вагинальный контрацептив |
| RU2184534C2 (ru) | 2000-04-27 | 2002-07-10 | Рудько Адолина Петровна | Антисептические таблетки |
| RU2185156C2 (ru) | 2000-06-26 | 2002-07-20 | Рудько Адолина Петровна | Интраназальный антисептик |
| RU2188005C2 (ru) | 2000-10-04 | 2002-08-27 | Рудько Адолина Петровна | Состав для антисептической обработки кожи рук и операционного поля |
| US20040033208A1 (en) | 2000-12-20 | 2004-02-19 | Cagle Gerald D. | Antifungal compositions containing an antibiotic and one or more amidoamines |
| WO2002049627A2 (en) * | 2000-12-20 | 2002-06-27 | Alcon, Inc. | Antifungal compositions containing an antibiotic and one or more amidoamines |
| RU2005100533A (ru) * | 2005-01-13 | 2006-06-20 | Открытое акционерное общество "Система-Венчур" (ОАО "Система-Венчур") (RU) | Средство для ускорения заживления раны |
| CN101562971A (zh) * | 2006-05-10 | 2009-10-21 | S.K.药物公司 | 协同增强的消毒溶液 |
| CN101100432B (zh) * | 2006-07-04 | 2010-08-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯甲基二甲基[3-(肉豆蔻酰胺基)丙基]氯化铵的合成方法 |
| DE102008039234A1 (de) * | 2007-10-29 | 2009-05-07 | Neudecker & Jolitz Gmbh & Co. | Motorisch betriebener Türöffner und Motor für einen Türöffner |
| UA30143U (en) | 2007-11-14 | 2008-02-11 | Валерий Михайлович Шарапов | Piezoelectric transformer |
-
2010
- 2010-02-19 WO PCT/EP2010/001056 patent/WO2011100994A1/de not_active Ceased
-
2011
- 2011-02-15 AU AU2011217530A patent/AU2011217530B2/en active Active
- 2011-02-15 ES ES11708184.4T patent/ES2524379T3/es active Active
- 2011-02-15 DK DK11708184.4T patent/DK2536400T3/en active
- 2011-02-15 EP EP11708184.4A patent/EP2536400B1/de active Active
- 2011-02-15 HR HRP20141173AT patent/HRP20141173T1/hr unknown
- 2011-02-15 CN CN201180014472.7A patent/CN102869354B/zh active Active
- 2011-02-15 SI SI201130337T patent/SI2536400T1/sl unknown
- 2011-02-15 GE GEAP201112831A patent/GEP20135942B/en unknown
- 2011-02-15 BR BR112012020828-4A patent/BR112012020828B1/pt not_active IP Right Cessation
- 2011-02-15 PT PT117081844T patent/PT2536400E/pt unknown
- 2011-02-15 WO PCT/EP2011/000691 patent/WO2011101113A1/de not_active Ceased
- 2011-02-15 KR KR1020127024396A patent/KR101744895B1/ko active Active
- 2011-02-15 EA EA201201158A patent/EA022283B1/ru unknown
- 2011-02-15 JP JP2012553213A patent/JP5746224B2/ja active Active
- 2011-02-15 MD MDA20120079A patent/MD4411C1/ro active IP Right Grant
- 2011-02-15 PL PL11708184T patent/PL2536400T3/pl unknown
- 2011-02-15 MX MX2012009646A patent/MX2012009646A/es active IP Right Grant
- 2011-02-15 UA UAA201210093A patent/UA103968C2/ru unknown
-
2012
- 2012-08-16 IL IL221501A patent/IL221501A/en active IP Right Grant
-
2014
- 2014-12-11 CY CY20141101033T patent/CY1115833T1/el unknown
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2459062A (en) * | 1944-02-08 | 1949-01-11 | American Cyanamid Co | Quaternary ammonium compounds |
| US4093711A (en) * | 1976-08-13 | 1978-06-06 | Noxell Corporation | Oral hygiene |
| SU1796185A1 (ru) * | 1990-06-23 | 1993-02-23 | Adolina P Rudko | Фунгицид 2 |
| WO1993000892A1 (fr) * | 1991-07-10 | 1993-01-21 | Jury Semenovich Krivoshein | Preparation pharmaceutique |
| RU2157214C2 (ru) * | 1998-04-16 | 2000-10-10 | Государственный научный центр лекарственных средств | Противовоспалительное и антимикробное лекарственное средство для местного применения |
| RU2161961C1 (ru) * | 2000-03-17 | 2001-01-20 | Кривошеин Юрий Семенович | Лекарственный препарат |
| UA64800C2 (uk) * | 2000-04-27 | 2004-03-15 | Юрій Семенович Кривошеін | Очний антисептик |
| UA67795C2 (uk) * | 2000-06-26 | 2004-07-15 | Yurii Semenovych Kryvoshein | Склад для лікування опікових ран, який включає мірамістин |
| US20040058924A1 (en) * | 2000-12-20 | 2004-03-25 | Schlitzer Ronald L. | Use of amidoamines to treat or prevent acanthamoeba and fungal infections |
| EP1634590A1 (de) * | 2003-06-04 | 2006-03-15 | Megainpharm GmbH | Coronavirus-inaktivierendes mittel |
| WO2007136558A2 (en) * | 2006-05-10 | 2007-11-29 | S.K. Pharmaceutical, Inc. | Synergistically enhanced disinfecting solutions |
| DE102008039254A1 (de) * | 2008-08-20 | 2010-02-25 | Megainpharm Gmbh | Arzneimittel |
Also Published As
| Publication number | Publication date |
|---|---|
| MD4411C1 (ro) | 2016-11-30 |
| BR112012020828B1 (pt) | 2021-01-12 |
| PT2536400E (pt) | 2014-11-27 |
| KR20130018242A (ko) | 2013-02-20 |
| BR112012020828A2 (pt) | 2016-06-28 |
| PL2536400T3 (pl) | 2015-04-30 |
| JP5746224B2 (ja) | 2015-07-08 |
| SI2536400T1 (sl) | 2015-01-30 |
| KR101744895B1 (ko) | 2017-06-08 |
| CN102869354B (zh) | 2015-12-16 |
| EA201201158A1 (ru) | 2013-02-28 |
| AU2011217530A1 (en) | 2012-09-13 |
| GEP20135942B (en) | 2013-10-10 |
| CN102869354A (zh) | 2013-01-09 |
| UA103968C2 (ru) | 2013-12-10 |
| WO2011100994A1 (de) | 2011-08-25 |
| AU2011217530B2 (en) | 2014-01-16 |
| HK1179164A1 (zh) | 2013-09-27 |
| WO2011101113A1 (de) | 2011-08-25 |
| MX2012009646A (es) | 2013-02-11 |
| IL221501A (en) | 2016-11-30 |
| DK2536400T3 (en) | 2014-12-15 |
| CY1115833T1 (el) | 2017-01-25 |
| HRP20141173T1 (hr) | 2015-01-30 |
| EP2536400B1 (de) | 2014-09-24 |
| EP2536400A1 (de) | 2012-12-26 |
| ES2524379T3 (es) | 2014-12-05 |
| MD20120079A2 (en) | 2013-01-31 |
| MD4411B1 (ro) | 2016-04-30 |
| JP2013519695A (ja) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8901172B2 (en) | Method for treating an inflammation or lesion caused by a virus | |
| CN1946428A (zh) | 具有治疗作用的抗微生物组合物和方法 | |
| US4873265A (en) | Anti-infective methods and compositions | |
| WO2009113910A1 (ru) | Гель, обладающий противовоспалительным и противоаллергическим действием | |
| CA2439413C (en) | Virucidal compositions | |
| EA022283B1 (ru) | Лекарственный препарат, содержащий бензилдиметил[3-(миристоиламино)пропил]аммония хлорид | |
| EP0191357A2 (en) | Treatment of eye inflammation with biphenamine | |
| RU2161961C1 (ru) | Лекарственный препарат | |
| RU2233151C2 (ru) | Применение тозилхлорамидов для лечения заболеваний кожи и слизистой оболочки | |
| US4929619A (en) | Anti-infective methods and compositions | |
| US4897404A (en) | Anti-infective methods and compositions | |
| RU2843470C1 (ru) | Средство по уходу за глазами животных | |
| US4895859A (en) | Anti-infective methods and compositions | |
| HK1179164B (en) | Pharmaceutical comprising myramistin | |
| US4895857A (en) | Anti-infective methods and compositions | |
| DE102008039254A1 (de) | Arzneimittel | |
| JP2006521298A (ja) | 物理的又は化学的因子により生じる非特異的炎症の治療及び抑制におけるｎ‐アセチル‐ｄ‐グルコサミンの使用 | |
| AU2008201666A1 (en) | Virucidal compositions | |
| WO2002067947A1 (fr) | Utilisation de n-acetyl-d-glucosamine dans la preparation de compositions pharmaceutiques utilisees dans le traitement adjuvant d'une maladie anoperineale |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| QB4A | Registration of a licence in a contracting state | ||
| QB4A | Registration of a licence in a contracting state |